Table 3.
Cases of advanced/metastatic urothelial carcinoma treated with erdafitinib with subsequent acquisition of new notable cfDNA alterations prior to or at the time of disease progression.
| Case ID | Pre-treatment FGFR2/3 alterations | Alterations acquired on erdafitinib related to TP53 and FGFR signaling | Best response to erdafitinib by RECIST v1.1 |
|---|---|---|---|
| P-0004257 | FGFR3 Y373C | TP53 K132M; TP53 R158L | PR |
| P-0033799 | FGFR3 S249C; FGFR3 S371C; FGFR3 R399C; FGFR3 R248C; TACC3-FGFR3 fusion | FGFR3 R669Ga,b; FGFR3 V553Ma; FGFR3 N540Sa,b; FGFR3 H673Y; FGFR3 K649_K650delinsIEb,c; TP53 S241C; BRAF-CLIP2 fusion | SD |
| P-0044554 | FGFR3 S249C | TP53 E287Q | PD |
| P-0037307 | FGFR3 S249C | FGFR3 V553Ma; FGFR3 K650Mb,c; FGFR2 R255W; AKT1 E17K | PR |
| P-0044518 | FGFR3 S249C | TP53 I195T | PR |
| P-0042869 | FGFR3 Y373C | TP53 R248W; TP53 S241Y | PR |
Abbreviations: cfDNA, cell-free DNA; PD, progression of disease; PR, partial response; SD, stable disease
a
Putative FGFR3 gatekeeper mutation based on in silico analysis and/or preclinical data.
b
Likely pathogenic FGFR3 mutation based on OncoKB.
c
Hotspot FGFR3 mutation per OncoKB.